COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effects of Modafinil on Olanzapine Weight Gain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00636896
Recruitment Status : Completed
First Posted : March 17, 2008
Last Update Posted : March 17, 2008
Eli Lilly and Company
University of North Dakota
Information provided by:
Neuropsychiatric Research Institute, Fargo, North Dakota

Brief Summary:

This study is designed as a 3 week, randomized, double blind, placebo controlled, trial. Olanzapine and modafinil will be titrated to 10mg and 200mg respectively. Feeding lab assessments will be conducted at baseline and endpoint. Assessments of hunger/satiety, kilocalories consumed and weight will be obtained. Plasma ghrelin and PYY3-36 levels will be drawn at baseline and endpoint prior to breakfast and two hours post.

Study hypothesis: The modafinil/olanzapine group will gain less weight than the olanzapine/placebo group over three weeks of drug intake.

Condition or disease Intervention/treatment Phase
Weight Gain Drug: Olanzapine plus modafinil Drug: Olanzapine plus placebo Not Applicable

Detailed Description:

Atypical antipsychotics have become the drugs of choice in the treatment of schizophrenia as well as acute and maintenance therapy for bipolar disorder. In addition, affective disorders have been found to benefit from these agents (Masan 2004). These disorders represent chronic conditions that require extended treatment for years if not lifetimes. In light of the ever widening use of the atypicals, attention must now be focused on adverse reactions that may limit compliance with these agents. Weight gain and sedation have proven to be associated with many atypicals (Allison et al. 1999; Wirshing et al. 1999) including clozapine, olanzapine, risperidone and quetiapine. These side effects can reduce compliance and have detrimental effects on patient's health over long term treatment.

In our previous study, olanzapine and risperidone were demonstrated to affect eating behaviors and weight/BMI compared to placebo in a 2 week paradigm in normal healthy human subjects. Behaviors affected included appetite, reported calories consumed per day, and observed calories consumed in a feeding laboratory. No effects were seen on resting energy expenditure corrected for lean body weight. Also, sedation was reported in 81.3 and 75 % of the olanzapine and risperidone groups respectively. Sedation was the primary reason, in both groups, for medication dose reductions.

Weight gain and sedation have been postulated to be associated with the blockade of central nervous system (CNS) histamine-1 receptors (H1) by the atypical agents (Heisler 1998; Wirshing et al. 1999). In light of this postulated mechanism, it is reasonable to assume that overcoming the H1 blockade with a histamine agonist may aid in reducing these side effects to a tolerable level. Thus, the following study is proposed.

This study is designed as a randomized double blind, parallel group trial to evaluate the effect of modafinil (a proposed H1 agonist) vs. placebo on eating parameters, weight/BMI and sedation in healthy human subjects receiving olanzapine over a three week study period. This project utilizes the current state of the art feeding lab procedures, as reviewed by Mitchell and colleagues (Mitchell et al. 1998), to better characterize the effect of modafinil on olanzapine associated eating behavior. This project will help to determine the efficacy of utilizing a H1 agonist as an adjunctive medication in patients receiving atypical antipsychotic therapy to prevent weight gain and excess sedation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Comparison of the Effects of Modafinil on Olanzapine Associated Eating Behaviors in Normal Human Subjects
Study Start Date : July 2006
Actual Primary Completion Date : August 2007
Actual Study Completion Date : August 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Body Weight

Arm Intervention/treatment
Experimental: 1
Olanzapine 10 mg plus modafinil 200 mg
Drug: Olanzapine plus modafinil
Olanzapine 10 mg/d plus modafinil 200 mg/d
Other Names:
  • Zyprexa
  • Provigil

Placebo Comparator: 2
Olanzapine plus Placebo
Drug: Olanzapine plus placebo
Olanzapine 10 mg/d plus placebo
Other Names:
  • Zyprexa
  • Provigil

Primary Outcome Measures :
  1. Change in weight [ Time Frame: 3 weeks ]

Secondary Outcome Measures :
  1. Change in Kilocalories consumed [ Time Frame: Over 3 weeks ]
  2. Change in Epworth sleep scale [ Time Frame: 3 weeks ]
  3. Change in Food Craving Inventory [ Time Frame: 3 weeks ]
  4. Change in delta ghrelin [ Time Frame: 3 weeks ]
  5. Change in delta PYY3-36 [ Time Frame: 3 weeks ]
  6. Change in satiety ratings [ Time Frame: 3 weeks ]
  7. Change in hunger ratings [ Time Frame: 3 weeks ]
  8. Adverse effect comparison [ Time Frame: 3 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male or female subjects between the ages of 18 and 60 years.
  • Women of child bearing potential must be practicing an accepted method of birth control (barrier method or oral contraceptive) and have a negative pregnancy test at baseline.
  • Subjects must be of good general health by history and physical exam.

Exclusion Criteria:

  • Subjects who are allergic to olanzapine or modafinil.
  • Subjects with a history of a neuroleptic malignant syndrome.
  • Subjects who have a body mass index at visit 2 less than 20 kg/m2 or greater than 27 kg/m2.
  • Subjects who are restrictive eaters according to the restraint subscale of the Eating Disorder Evaluation (EDE).
  • Women who are pregnant or nursing at the time of the study.
  • Subjects who are lactose intolerant.
  • Subjects with diabetes mellitus.
  • Subjects experiencing clinically significant, unstable neurological, cardiac (including cardiac conduction defects), hepatic, renal disease or narrow angle glaucoma.
  • Subjects diagnosed with anorexia nervosa, bulimia nervosa, or binge eating disorder.
  • Subjects currently or with a past history of meeting DSM-IV diagnostic criteria for schizophrenia, schizoaffective disorder, bipolar disorder or substance abuse.
  • Subjects who have participated in an investigational drug study in past 30 days.
  • Subjects who are receiving any prescription medications other than oral contraceptives that would interact with the study medication or influence appetite or weight.
  • Subjects who smoke or use any nicotine products.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00636896

Layout table for location information
United States, North Dakota
Neuropsychiatric Research Institute
Fargo, North Dakota, United States, 58103
Sponsors and Collaborators
Neuropsychiatric Research Institute, Fargo, North Dakota
Eli Lilly and Company
University of North Dakota
Layout table for investigator information
Principal Investigator: James L Roerig, PharmD University of North Dakota
Additional Information:
Layout table for additonal information
Responsible Party: James L. Roerig Pharm.D. Principal Investigator, University of North Dakota Identifier: NCT00636896    
Other Study ID Numbers: FID-US-X297
First Posted: March 17, 2008    Key Record Dates
Last Update Posted: March 17, 2008
Last Verified: March 2008
Keywords provided by Neuropsychiatric Research Institute, Fargo, North Dakota:
weight gain
atypical antipsychotic
Additional relevant MeSH terms:
Layout table for MeSH terms
Weight Gain
Body Weight
Body Weight Changes
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Central Nervous System Stimulants
Wakefulness-Promoting Agents
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers